Boothbay Fund Management’s Palvella Therapeutics PVLA Stock Holding History

Boothbay Fund Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-18,962	Closed	-$2.36M	–	2719
2026 Q1	$2.36M	Buy	+18,962	New	+$1.98M	0.03%	547
2025 Q4	–	Sell	-25,532	Closed	-$1.6M	–	2465
2025 Q3	$1.6M	Buy	+25,532	New	+$1.14M	0.02%	654
2022 Q2	–	Sell	-609	Closed	-$148K	–	2739
2022 Q1	$148K	Sell	609 -204	-25%	-$53.6K	﹤0.01%	1998
2021 Q4	$246K	Hold	813	–	–	0.01%	1362
2021 Q3	$336K	Buy	+813	New	+$283K	0.01%	1270
2020 Q3	–	Sell	-352	Closed	-$87K	–	1260
2020 Q2	$87K	Buy	352 +17	+5%	+$3.98K	0.01%	892
2020 Q1	$61K	Buy	+335	New	+$84.4K	0.01%	773
2019 Q4	–	Sell	-423	Closed	-$115K	–	1024
2019 Q3	$115K	Sell	423 -450	-52%	-$174K	0.01%	694
2019 Q2	$328K	Buy	+873	New	+$260K	0.03%	515

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Boothbay Fund Management's PVLA Position: Q2 2026 in Review

Boothbay Fund Management sold out of Palvella Therapeutics (PVLA) in Q2 2026, closing a stake of 18,962 shares — an estimated $2.36M sold.

Boothbay Fund Management first reported a position in PVLA in Q2 2019 and held it in 9 quarters. The position peaked at $2.36M in Q1 2026. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

Boothbay Fund Management reported no remaining Palvella Therapeutics position as of Q2 2026 after selling out during the quarter.
Boothbay Fund Management sold 18,962 Palvella Therapeutics shares in Q2 2026, an estimated $2.36M.
Boothbay Fund Management first reported a position in Palvella Therapeutics in Q2 2019 and held it in 9 quarters.
Boothbay Fund Management's Palvella Therapeutics position peaked at $2.36M in Q1 2026.
196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.